GW Pharmaceuticals PLC- (NASDAQ:GWPH) was upgraded by Goldman Sachs Group from a “neutral” rating to a “buy” rating in a report released on Thursday.

Several other equities analysts also recently issued reports on the stock. Cantor Fitzgerald set a $208.00 price objective on shares of GW Pharmaceuticals PLC- and gave the company a “buy” rating in a report on Monday, December 4th. Bank of America decreased their price objective on shares of GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating on the stock in a report on Tuesday, November 14th. ValuEngine downgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Cowen reaffirmed an “outperform” rating and set a $165.00 price objective on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $153.00 price objective (down from $160.00) on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $143.22.

GW Pharmaceuticals PLC- (NASDAQ GWPH) opened at $123.98 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.59 and a quick ratio of 7.47. GW Pharmaceuticals PLC- has a twelve month low of $92.65 and a twelve month high of $136.95.

Several large investors have recently bought and sold shares of the company. Royal Bank of Canada lifted its stake in shares of GW Pharmaceuticals PLC- by 0.4% in the second quarter. Royal Bank of Canada now owns 4,240 shares of the biopharmaceutical company’s stock worth $424,000 after buying an additional 18 shares in the last quarter. IHT Wealth Management LLC lifted its stake in shares of GW Pharmaceuticals PLC- by 18.0% in the second quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 100 shares in the last quarter. Advisor Group Inc. lifted its stake in shares of GW Pharmaceuticals PLC- by 10.7% in the second quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 145 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in shares of GW Pharmaceuticals PLC- by 8.5% in the second quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 162 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. lifted its stake in shares of GW Pharmaceuticals PLC- by 18.6% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 3,700 shares of the biopharmaceutical company’s stock worth $376,000 after buying an additional 581 shares in the last quarter. 81.85% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/12/14/gw-pharmaceuticals-plc-gwph-lifted-to-buy-at-goldman-sachs-group.html.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.